Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8121468 | 0.77 | MAPT (0.52) | MAPTMAPK1ALDH1A1PDE4BPOLB | |
| SCHEMBL31452713 | 0.75 | GABRA1 (0.39) | EPHX2ALDH1A1PDE10AKDM4E | |
| SCHEMBL5548596 | 0.75 | CHRM5 (0.38) | MAPTMAPK1 | |
| SCHEMBL12075244 | 0.74 | EPHX2 (0.45) | MAPTEPHX2ALDH1A1NPC1RAB9A | |
| SCHEMBL5551717 | 0.72 | KMT2A (0.46) | MAPTEPHX2ALDH1A1NPC1RAB9A | |
| SCHEMBL5547613 | 0.71 | KDM4E (0.31) | ALDH1A1KDM4E | |
| SCHEMBL5551857 | 0.70 | KMT2A (0.38) | MAPTALDH1A1KDM4E | |
| SCHEMBL8126331 | 0.69 | KDM4E (0.46) | MAPTMAPK1ALDH1A1NPC1RAB9A | |
| SCHEMBL8111372 | 0.69 | MMP13 (0.37) | ALDH1A1KDM4E | |
| SCHEMBL8120652 | 0.68 | MAPT (0.46) | MAPTMAPK1ALDH1A1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211673-B2 | 4-trifluoromethylpyrazolyl-substituted pyridines and pyrimidines | BAYER CROPSCIENCE GMBH (DE) | 2007-05-01 | — | — | US | disclosed |
| US-20060122063-A1 | 5-methyl-2-(4-trifluoromethyl-1H-1-pyrazolyl)-4-(5-trifluoromethyl-3-thienyloxy)pyrimidine; broadleaf herbicide | BAYER CROPSCIENCE GMBH (DE) | 2006-06-08 | — | — | US | disclosed |
| US-7022650-B2 | 4-trifluoromethylpyrazolyl-substituted pyridines and pyrimidines | BAYER CROPSCIENCE GMBH (DE) | 2006-04-04 | — | — | US | disclosed |
| EP-1527069-A2 | PYRIDINES AND PYRIMIDINES SUBSTITUTED BY 4-TRIFLUOROMETHYLPYRAZOLYL | Bayer CropScience GmbH (DE) | 2005-05-04 | — | — | EP | disclosed |
| US-20040072692-A1 | 4-trifluoromethylpyrazolyl-substituted pyridines and pyrimidines | BAYER CROPSCIENCE AG (DE) | 2004-04-15 | — | — | US | disclosed |
| WO-2004013131-A2 | PYRIDINES AND PYRIMIDINES SUBSTITUTED BY 4-TRIFLUOROMETHYLPYRAZOLYL | BAYER CROPSCIENCE GMBH (DE) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072692-A1 | 4-trifluoromethylpyrazolyl-substituted pyridines and pyrimidines | CYP4X1, ROS1, NOX4 | MAPT 3908/4885MAPK1 1700/4885EPHX2 1008/4885 |
| US-20060122063-A1 | 5-methyl-2-(4-trifluoromethyl-1H-1-pyrazolyl)-4-(5-trifluoromethyl-3-thienyloxy)pyrimidine; broadleaf herbicide | CYP2F1, CYP4F2, CYP4F3 | MAPT 3545/4885MAPK1 3549/4885EPHX2 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.